Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry
Entity
UAM. Departamento de MedicinaPublisher
WileyDate
2018-10-03Citation
10.1111/apt.14930
Alimentary Pharmacology and Therapeutics 48.8 (2018): 839-851
ISSN
1365-2036 (online); 0269-2813 (print)DOI
10.1111/apt.14930Editor's Version
https://doi.org/10.1111/apt.14930Subjects
MedicinaNote
Artículo escrito por un elevado número de autores, solo se referencian el que aparece en primer lugar, el nombre del grupo de colaboración, si lo hubiere, y los autores pertenecientes a la UAMRights
© 2018 John Wiley & SonsAbstract
Effectiveness of vedolizumab in real world clinical practice is unknown. Aim, To evaluate the short and long-term effectiveness of vedolizumab in patients with inflammatory bowel disease (IBD). Methods Patients who received at least 1 induction dose of vedolizumab were included. Effectiveness was defined based on Harvey-Bradshaw index (HBI) in Crohn's disease (CD) and Partial Mayo Score (PMS) in ulcerative colitis (UC). Short-term response was assessed at week 14. Variables associated with short-term remission were identified by logistic regression analysis. The Kaplan-Meier method was used to evaluate the long-term durability of vedolizumab treatment. Cox model was used to identify factors associated with discontinuation of treatment and loss of response. Results: 521 patients were included (median follow-up 10 months [interquartile range 5-18 months]). At week 14, 46.8% had remission and 15.7% clinical response. CD (vs UC), previous surgery, higher CRP concentration and disease severity at baseline were significantly associated with impaired response. The rate of vedolizumab discontinuation was 37% per patient-year of follow-up (27.6% in UC and 45.3% in CD, P < 0.01). CD (vs UC), anaemia at baseline, steroids during induction and CRP concentration were associated with lower durability of treatment. Seven per cent of patients developed adverse events, infections being the most frequent.
Conclusions Over 60% of IBD patients respond to vedolizumab. Many patients discontinue treatment over time. CD and disease burden impair both short- and long-term response. Vedolizumab seems to be safe in clinical practice
Files in this item
Google Scholar:Chaparro Sánchez, María
-
Pérez Gisbert, Francisco Javier
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.